Trials / No Longer Available
No Longer AvailableNCT03420430
Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Genelux Corporation · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- —
Summary
GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical trial. Expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of care options for treatment. Potential patients will be evaluated individually depending on GL-ONC1 product supply.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GL-ONC1 |
Timeline
- First posted
- 2018-02-05
- Last updated
- 2024-09-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03420430. Inclusion in this directory is not an endorsement.